http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 16 Jul 2026 17:40:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GALECTIN+THERAPEUTICS+++++For%3A+Jul+14++Filed+by%3A+Jamil+Khurram/26780744.html si-local-file:///var/storage/secattach/20260716/26780744.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GALECTIN+THERAPEUTICS+++++For%3A+Jul+14++Filed+by%3A+Jamil+Khurram/26780744.html Thu, 16 Jul 2026 17:40:00 -0400 GALT O.01956176 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GALECTIN+THERAPEUTICS+++++For%3A+Jul+14++Filed+by%3A+Jamil+Khurram/26780744.html si-local-file:///var/storage/secattach/20260716/26780744.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GALECTIN+THERAPEUTICS+++++For%3A+Jul+14++Filed+by%3A+Jamil+Khurram/26780744.html Thu, 16 Jul 2026 17:40:00 -0400 GALT O.01956176 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GALECTIN+THERAPEUTICS+++++For%3A+Jun+26++Filed+by%3A+Shlevin+Harold+H./26715187.html si-local-file:///var/storage/secattach/20260630/26715187.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GALECTIN+THERAPEUTICS+++++For%3A+Jun+26++Filed+by%3A+Shlevin+Harold+H./26715187.html Tue, 30 Jun 2026 19:24:00 -0400 GALT O.01956176 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GALECTIN+THERAPEUTICS+++++For%3A+Jun+26++Filed+by%3A+Shlevin+Harold+H./26715187.html si-local-file:///var/storage/secattach/20260630/26715187.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GALECTIN+THERAPEUTICS+++++For%3A+Jun+26++Filed+by%3A+Shlevin+Harold+H./26715187.html Tue, 30 Jun 2026 19:24:00 -0400 GALT O.01956176 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GALECTIN+THERAPEUTICS+++++For%3A+Jun+26++Filed+by%3A+Jamil+Khurram/26715185.html si-local-file:///var/storage/secattach/20260630/26715185.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GALECTIN+THERAPEUTICS+++++For%3A+Jun+26++Filed+by%3A+Jamil+Khurram/26715185.html Tue, 30 Jun 2026 19:23:00 -0400 GALT O.01956176 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GALECTIN+THERAPEUTICS+++++For%3A+Jun+26++Filed+by%3A+Jamil+Khurram/26715185.html si-local-file:///var/storage/secattach/20260630/26715185.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GALECTIN+THERAPEUTICS+++++For%3A+Jun+26++Filed+by%3A+Jamil+Khurram/26715185.html Tue, 30 Jun 2026 19:23:00 -0400 GALT O.01956176 http://www.streetinsider.com/SEC+Filings/Form++144++++++++GALECTIN+THERAPEUTICS++++++++++++++++++Filed+by%3A+Shlevin+Harold+H./26706525.html si-local-file:///var/storage/secattach/20260629/26706525.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++GALECTIN+THERAPEUTICS++++++++++++++++++Filed+by%3A+Shlevin+Harold+H./26706525.html Mon, 29 Jun 2026 16:10:00 -0400 GALT O.01956176 http://www.streetinsider.com/SEC+Filings/Form++144++++++++GALECTIN+THERAPEUTICS++++++++++++++++++Filed+by%3A+Shlevin+Harold+H./26706525.html si-local-file:///var/storage/secattach/20260629/26706525.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++GALECTIN+THERAPEUTICS++++++++++++++++++Filed+by%3A+Shlevin+Harold+H./26706525.html Mon, 29 Jun 2026 16:10:00 -0400 GALT O.01956176 http://www.streetinsider.com/SEC+Filings/Form++144++++++++GALECTIN+THERAPEUTICS++++++++++++++++++Filed+by%3A+Jamil+Khurram/26700159.html si-local-file:///var/storage/secattach/20260626/26700159.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++GALECTIN+THERAPEUTICS++++++++++++++++++Filed+by%3A+Jamil+Khurram/26700159.html Fri, 26 Jun 2026 18:09:00 -0400 GALT O.01956176 http://www.streetinsider.com/SEC+Filings/Form++144++++++++GALECTIN+THERAPEUTICS++++++++++++++++++Filed+by%3A+Jamil+Khurram/26700159.html si-local-file:///var/storage/secattach/20260626/26700159.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++GALECTIN+THERAPEUTICS++++++++++++++++++Filed+by%3A+Jamil+Khurram/26700159.html Fri, 26 Jun 2026 18:09:00 -0400 GALT O.01956176 http://www.streetinsider.com/SEC+Filings/Form++144++++++++GALECTIN+THERAPEUTICS++++++++++++++++++Filed+by%3A+Shlevin+Harold+H./26698886.html si-local-file:///var/storage/secattach/20260626/26698886.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++GALECTIN+THERAPEUTICS++++++++++++++++++Filed+by%3A+Shlevin+Harold+H./26698886.html Fri, 26 Jun 2026 16:15:00 -0400 GALT O.01956176 http://www.streetinsider.com/SEC+Filings/Form++144++++++++GALECTIN+THERAPEUTICS++++++++++++++++++Filed+by%3A+Shlevin+Harold+H./26698886.html si-local-file:///var/storage/secattach/20260626/26698886.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++GALECTIN+THERAPEUTICS++++++++++++++++++Filed+by%3A+Shlevin+Harold+H./26698886.html Fri, 26 Jun 2026 16:15:00 -0400 GALT O.01956176 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GALECTIN+THERAPEUTICS+++++For%3A+Jun+23++Filed+by%3A+Jamil+Khurram/26692330.html si-local-file:///var/storage/secattach/20260625/26692330.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GALECTIN+THERAPEUTICS+++++For%3A+Jun+23++Filed+by%3A+Jamil+Khurram/26692330.html Thu, 25 Jun 2026 16:06:00 -0400 GALT O.01956176 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GALECTIN+THERAPEUTICS+++++For%3A+Jun+23++Filed+by%3A+Jamil+Khurram/26692330.html si-local-file:///var/storage/secattach/20260625/26692330.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GALECTIN+THERAPEUTICS+++++For%3A+Jun+23++Filed+by%3A+Jamil+Khurram/26692330.html Thu, 25 Jun 2026 16:06:00 -0400 GALT O.01956176 http://www.streetinsider.com/SEC+Filings/Form++144++++++++GALECTIN+THERAPEUTICS++++++++++++++++++Filed+by%3A+Jamil+Khurram/26679657.html si-local-file:///var/storage/secattach/20260623/26679657.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++GALECTIN+THERAPEUTICS++++++++++++++++++Filed+by%3A+Jamil+Khurram/26679657.html Tue, 23 Jun 2026 16:15:00 -0400 GALT O.01956176 http://www.streetinsider.com/SEC+Filings/Form++144++++++++GALECTIN+THERAPEUTICS++++++++++++++++++Filed+by%3A+Jamil+Khurram/26679657.html si-local-file:///var/storage/secattach/20260623/26679657.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++GALECTIN+THERAPEUTICS++++++++++++++++++Filed+by%3A+Jamil+Khurram/26679657.html Tue, 23 Jun 2026 16:15:00 -0400 GALT O.01956176 http://www.streetinsider.com/FDA/Galectin+reaches+FDA+agreement+on+belapectin+Phase+3+trial+design/26676135.html <p>Galectin Therapeutics Inc. (NASDAQ: GALT) announced it has reached agreement with the U.S. Food and Drug Administration on key elements of a planned Phase 3 trial for belapectin, a drug candidate targeting metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension.</p> <p>The agreement followed an in-person Type C meeting with the FDA and covers the study's primary endpoint, central endoscopy review methodology, and regulatory pathway. The primary endpoint will be a composite liver outcome that includes prevention of the development of large esophageal varices greater than 5 mm, a marker of worsening portal hypertension in patients with compensated MASH cirrhosis.</p> <p>The FDA accepted http://www.streetinsider.com/FDA/Galectin+reaches+FDA+agreement+on+belapectin+Phase+3+trial+design/26676135.html Tue, 23 Jun 2026 08:00:35 -0400 A.06822034 GALT O.01956176 O.20026344 http://www.streetinsider.com/FDA/Galectin+reaches+FDA+agreement+on+belapectin+Phase+3+trial+design/26676135.html <p>Galectin Therapeutics Inc. (NASDAQ: GALT) announced it has reached agreement with the U.S. Food and Drug Administration on key elements of a planned Phase 3 trial for belapectin, a drug candidate targeting metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension.</p> <p>The agreement followed an in-person Type C meeting with the FDA and covers the study's primary endpoint, central endoscopy review methodology, and regulatory pathway. The primary endpoint will be a composite liver outcome that includes prevention of the development of large esophageal varices greater than 5 mm, a marker of worsening portal hypertension in patients with compensated MASH cirrhosis.</p> <p>The FDA accepted http://www.streetinsider.com/FDA/Galectin+reaches+FDA+agreement+on+belapectin+Phase+3+trial+design/26676135.html Tue, 23 Jun 2026 08:00:35 -0400 A.06822034 GALT O.01956176 O.20026344 http://www.streetinsider.com/FDA/Galectin+reaches+FDA+agreement+on+belapectin+Phase+3+trial+design/26676135.html <p>Galectin Therapeutics Inc. (NASDAQ: GALT) announced it has reached agreement with the U.S. Food and Drug Administration on key elements of a planned Phase 3 trial for belapectin, a drug candidate targeting metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension.</p> <p>The agreement followed an in-person Type C meeting with the FDA and covers the study's primary endpoint, central endoscopy review methodology, and regulatory pathway. The primary endpoint will be a composite liver outcome that includes prevention of the development of large esophageal varices greater than 5 mm, a marker of worsening portal hypertension in patients with compensated MASH cirrhosis.</p> <p>The FDA accepted http://www.streetinsider.com/FDA/Galectin+reaches+FDA+agreement+on+belapectin+Phase+3+trial+design/26676135.html Tue, 23 Jun 2026 08:00:35 -0400 A.06822034 GALT O.01956176 O.20026344 http://www.streetinsider.com/FDA/Galectin+reaches+FDA+agreement+on+belapectin+Phase+3+trial+design/26676135.html <p>Galectin Therapeutics Inc. (NASDAQ: GALT) announced it has reached agreement with the U.S. Food and Drug Administration on key elements of a planned Phase 3 trial for belapectin, a drug candidate targeting metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension.</p> <p>The agreement followed an in-person Type C meeting with the FDA and covers the study's primary endpoint, central endoscopy review methodology, and regulatory pathway. The primary endpoint will be a composite liver outcome that includes prevention of the development of large esophageal varices greater than 5 mm, a marker of worsening portal hypertension in patients with compensated MASH cirrhosis.</p> <p>The FDA accepted http://www.streetinsider.com/FDA/Galectin+reaches+FDA+agreement+on+belapectin+Phase+3+trial+design/26676135.html Tue, 23 Jun 2026 08:00:35 -0400 A.06822034 GALT O.01956176 O.20026344 http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Announces+Positive+Type+C+Meeting+with+the+FDA+for+Belapectin+in+Patients+with+MASH+Cirrhosis+and+Portal+Hypertension/26676071.html <ul type="disc"><li style="margin-bottom:8pt;">Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectin</li><li style="margin-bottom:8pt;">Company intends to file the Phase 3 protocol in Q3 2026 and is actively exploring strategic and financial partnership opportunities to support the continued development and commercialization of belapectin<br/><br/></li></ul> <p>NORCROSS, Ga., June 23, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), a biotechnology company focused on developing therapies for patients with advanced liver disease, today announced positive feedback from its recent in person Type C meeting with the U.S. Food and Drug http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Announces+Positive+Type+C+Meeting+with+the+FDA+for+Belapectin+in+Patients+with+MASH+Cirrhosis+and+Portal+Hypertension/26676071.html Tue, 23 Jun 2026 08:00:00 -0400 A.06822034 GALT O.01956176 O.20026344 http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Announces+Positive+Type+C+Meeting+with+the+FDA+for+Belapectin+in+Patients+with+MASH+Cirrhosis+and+Portal+Hypertension/26676071.html <ul type="disc"><li style="margin-bottom:8pt;">Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectin</li><li style="margin-bottom:8pt;">Company intends to file the Phase 3 protocol in Q3 2026 and is actively exploring strategic and financial partnership opportunities to support the continued development and commercialization of belapectin<br/><br/></li></ul> <p>NORCROSS, Ga., June 23, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), a biotechnology company focused on developing therapies for patients with advanced liver disease, today announced positive feedback from its recent in person Type C meeting with the U.S. Food and Drug http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Announces+Positive+Type+C+Meeting+with+the+FDA+for+Belapectin+in+Patients+with+MASH+Cirrhosis+and+Portal+Hypertension/26676071.html Tue, 23 Jun 2026 08:00:00 -0400 A.06822034 GALT O.01956176 O.20026344 http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Announces+Positive+Type+C+Meeting+with+the+FDA+for+Belapectin+in+Patients+with+MASH+Cirrhosis+and+Portal+Hypertension/26676071.html <ul type="disc"><li style="margin-bottom:8pt;">Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectin</li><li style="margin-bottom:8pt;">Company intends to file the Phase 3 protocol in Q3 2026 and is actively exploring strategic and financial partnership opportunities to support the continued development and commercialization of belapectin<br/><br/></li></ul> <p>NORCROSS, Ga., June 23, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), a biotechnology company focused on developing therapies for patients with advanced liver disease, today announced positive feedback from its recent in person Type C meeting with the U.S. Food and Drug http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Announces+Positive+Type+C+Meeting+with+the+FDA+for+Belapectin+in+Patients+with+MASH+Cirrhosis+and+Portal+Hypertension/26676071.html Tue, 23 Jun 2026 08:00:00 -0400 A.06822034 GALT O.01956176 O.20026344 http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Announces+Positive+Type+C+Meeting+with+the+FDA+for+Belapectin+in+Patients+with+MASH+Cirrhosis+and+Portal+Hypertension/26676071.html <ul type="disc"><li style="margin-bottom:8pt;">Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectin</li><li style="margin-bottom:8pt;">Company intends to file the Phase 3 protocol in Q3 2026 and is actively exploring strategic and financial partnership opportunities to support the continued development and commercialization of belapectin<br/><br/></li></ul> <p>NORCROSS, Ga., June 23, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), a biotechnology company focused on developing therapies for patients with advanced liver disease, today announced positive feedback from its recent in person Type C meeting with the U.S. Food and Drug http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Announces+Positive+Type+C+Meeting+with+the+FDA+for+Belapectin+in+Patients+with+MASH+Cirrhosis+and+Portal+Hypertension/26676071.html Tue, 23 Jun 2026 08:00:00 -0400 A.06822034 GALT O.01956176 O.20026344 http://www.streetinsider.com/Globe+Newswire/Galectin+Therapeutics+Announces+Positive+Type+C+Meeting+with+the+FDA+for+Belapectin+in+Patients+with+MASH+Cirrhosis+and+Portal+Hypertension/26676071.html <ul type="disc"><li style="margin-bottom:8pt;">Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectin</li><li style="margin-bottom:8pt;">Company intends to file the Phase 3 protocol in Q3 2026 and is actively exploring strategic and financial partnership opportunities to support the continued development and commercialization of belapectin<br/><br/></li></ul> <p>NORCROSS, Ga., June 23, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), a biotechnology company focused on developing therapies for patients with advanced liver disease, today announced positive feedback from its recent in person Type C meeting with the U.S. Food and Drug http://www.streetinsider.com/Globe+Newswire/Galectin+Therapeutics+Announces+Positive+Type+C+Meeting+with+the+FDA+for+Belapectin+in+Patients+with+MASH+Cirrhosis+and+Portal+Hypertension/26676071.html Tue, 23 Jun 2026 08:00:00 -0400 A.06822034 GALT O.01956176 O.20026344